{
    "clinical_study": {
        "@rank": "90661", 
        "acronym": "ATOM", 
        "arm_group": [
            {
                "arm_group_label": "mFOLFOX + Bmab", 
                "arm_group_type": "Experimental", 
                "description": "mFOLFOX plus bevacizumab"
            }, 
            {
                "arm_group_label": "mFOLFOX + Cmab", 
                "arm_group_type": "Active Comparator", 
                "description": "mFOLFOX plus cetuximab"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and\n      mFOLFOX6+cetuximab for KRAS wild type colorectal cancer patients with liver limited\n      metastasis."
        }, 
        "brief_title": "Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases", 
        "condition": "Liver Only Metastasis From KRAS Wild Type Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Description: The purpose of this study is to evaluate efficacy and safety of\n      mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for KRAS wild type colorectal cancer patients\n      with liver limited metastasis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histopathologically confirmed colorectal cancer (adenocarcinoma) excluding vermiform\n             appendix cancer and proctos cancer.\n\n          2. EGFR positive\n\n          3. KRAS wild type\n\n          4. Synchronous* or metachronous liver limited metastasis with no extrahepatic disease\n\n               -  shychronous liver limited metastasis with primary lesion less than two thirds of\n                  the circumference\n\n               -  patients with primary lesion more than two thirds of the circumference can be\n                  enrolled after primary resection\n\n          5. Patients who has one or more lesion(s) of diameter 1 cm or larger (RECEST v1.1) be\n             able to assess continuously on the basis of the protocol by contrast enhanced CT or\n             contrast enhanced MRI of the liver:\n\n        (1)Liver metastases 5 or more (2)Liver metastases with 5 cm or larger in greatest\n        dimension (3)Unresectable considering remaining hepatic function (4)Invasion into all\n        hepatic veins or inferior vena cava (5)Invasion into both right and left hepatic arteries\n        or portal veins 6.No prior chemotherapy for colorectal cancer including hepatic arterial\n        infusion. Excluding postoperative and preoperative chemoradiotherapy except for rectal\n        cancer with synchronous liver metastases. Patients received postoperative chemotherapy\n        containing oxaliplatin have to be enrolled after 24 weeks from the last oxaliplatin\n        administration.\n\n        7.No previous treatment including ablation therapy, cryotherapy and chemotherapy for\n        metastases 8.Age at enrollment is >=20 and =<80 years 9.The Eastern Cooperative Oncology\n        Group (ECOG) Performance Status 0-1 10.Life expectancy from the day of enrollment is 3\n        months or longer 11.Major organ functions less than 14 days prior to entry meet the\n        following criteria.\n\n          1. Neu >= 1500/mm3\n\n          2. Pt >= 10.0x10^4/mm3\n\n          3. Hb >= 9.0 g/dL\n\n          4. T-bil =< 2.0 mg/dL\n\n          5. AST and ALT =< 200 IU/L\n\n          6. sCr =< 1.20 mg/dL\n\n          7. INR < 1.5\n\n          8. Proteinuria =< 2+ 12.Written informed consent\n\n        Exclusion Criteria:\n\n          1. Previously experienced severe allergic reaction to drugs\n\n          2. Receiving anti-platelet drugs (aspirin >= 325 mg/day) or NSAIDs\n\n          3. Receiving chronic systemic corticosteroid treatment\n\n          4. Surgery/ biopsy with skin incision or traumatic injury with suture less than 28 days\n             prior to entry. Excluding, suture for implanted venous reservoirs with catherter is\n             allowed.\n\n          5. Severe postoperative complications (e.g. postoperative infection, anastomic\n             dehiscence or paralytic ileus)\n\n          6. Diagnosed as hereditary colorectal cancer\n\n          7. Active other malignancies\n\n          8. Cerebrovascular disease or symptoms less than 1 year prior to entry\n\n          9. Pleural effusion, ascites or cardiac effusion requiring drainage\n\n         10. Hemorrhage/bleeding, paralytic ileus, obstruction or ulceration of gastrointestinal\n             tract\n\n         11. Perforation of gastrointestinal tract less than 1 year prior to entry\n\n         12. Presence of active infection\n\n         13. HBs antigen or HCV antibody positive\n\n         14. Uncontrolled comorbidity including hypertension, diabetes, arrhythmia, or other\n             diseases (such as cardiac disorder, interstitial pneumonia or renal disorder)\n\n         15. Presence of >= grade 2 diarrhea\n\n         16. Presence of >= grade 1 peripheral neuropathy\n\n         17. Pregnant or lactating women. Women and men with childbearing potential unwilling to\n             use effective means of contraception\n\n         18. Psychosis or psychiatric symptoms who are not able to comply with the protocol\n\n         19. Any other medical conditions disable to comply with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836653", 
            "org_study_id": "ATOM", 
            "secondary_id": "UMIN000010209"
        }, 
        "intervention": [
            {
                "arm_group_label": "mFOLFOX + Bmab", 
                "description": "5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "mFOLFOX + Cmab", 
                "description": "250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "L-OHP", 
                "intervention_type": "Drug", 
                "other_name": "Oxaliplatin"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "l-LV", 
                "intervention_type": "Drug", 
                "other_name": "Levofolinate"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "Fluorouracil"
            }, 
            {
                "arm_group_label": [
                    "mFOLFOX + Bmab", 
                    "mFOLFOX + Cmab"
                ], 
                "description": "2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.  Liver resection if resectable after 8 cycles or continue until progression of disease.", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "Fluorouracil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Bevacizumab", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Bevacizumab", 
            "Cetuximab", 
            "KRAS wild type colorectal cancer", 
            "liver metastasis"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "contact": {
                "email": "prj-atomdc@eps.co.jp", 
                "last_name": "Tatsumi Shimizu", 
                "phone": "+81-3-5684-7767"
            }, 
            "facility": {
                "address": {
                    "city": "Bunkyo-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "112-0004"
                }, 
                "name": "EPS Corporation"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer", 
        "other_outcome": [
            {
                "measure": "Tumor shrinkage rate", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "measure": "Liver resection rate", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "description": "pathologically confirmed R0 liver resection rate", 
                "measure": "R0 liver resection rate", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "description": "CT/MRI image assessed by the attending physician", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "measure": "Time to treatment-failure", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "assessed every 8 weeks"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "assessed every 16 weeks"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "all adverse events reported every two weeks during the study period [up to 4years]"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Graduate School of Medical Science, Kyushu University, Department of Surgery and Science", 
                "last_name": "Yoshihiko Maehara, MD,PhD,FACS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hyogo College of Medicine, Department of Surgery", 
                "last_name": "Naohiro Tomita, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tsukuba University, Graduate School of Medicine", 
                "last_name": "Ichinosuke Hyodo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tohoku University, Division of Gastroenterological Surgery", 
                "last_name": "Michiaki Unno, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Centrally reviewed progression-free survival assessed by CT image", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "assessed  every 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "assessed every 8 weeks"
        }, 
        "source": "EPS Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EPS Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}